一个新的FOXM1-BCL2A1轴决定了AML中对venetoclax的不利反应
Sanjeev Raghuwanshi1, Ahmed Magdy2, Nissim Hay2
1University of Illinois at Chicago, Department of Medicine, Chicago, Illinois, USA.
The Journal of biological chemistry
|January 29, 2025
概括
在急性髓性白血病 (AML) 中,蛋白质FOXM1 (叉头盒M1) 通过增加BCL2A1.1.来驱动对venetoclax的耐药性. 抑制这个FOXM1-BCL2A1轴使AML细胞对venetoclax治疗敏感.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 叉头盒M1 (FOXM1) 在急性髓性白血病 (AML) 中过度表达,与预后不佳和治疗阻力相关.
- 在AML中的NPM1突变可以使FOXM1失活,从而导致有利的结果.
- 通过BCL2A1蛋白的上调,可以产生对BCL2抑制剂venetoclax的耐药性.
研究的目的:
- 研究FOXM1-BCL2A1轴在AML中的venetoclax耐药性中的作用.
- 为了确定FOXM1是否通过BCL2A1上调促进venetoclax耐药性.
- 评估针对FOXM1-BCL2A1轴的治疗策略.
主要方法:
- 在AML模型中研究了FOXM1-BCL2A1相互作用.
- 在高FOXM1水平的AML细胞中利用了BCL2A1的基因淘汰.
- 与FOXM1抑制剂STL001.1联合使用的venetoclax.
主要成果:
- 发现FOXM1通过上调BCL2A1.1的调节来抑制AML中的venetoclax诱导的亡.
- 当FOXM1高度表达时,BCL2A1对venetoclax敏感的AML细胞被击败.
- 将venetoclax与FOXM1抑制剂STL001结合使用,抑制了BCL2A1并克服了venetoclax耐药性.
结论:
- FOXM1-BCL2A1轴是AML中venetoclax抵抗的一个关键机制.
- 向BCL2A1或抑制FOXM1可以使AML细胞对venetoclax敏感.
- 对FOXM1-BCL2A1轴的药理抑制是AML的一种潜在的治疗策略.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
The Intrinsic Apoptotic Pathway
6.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
T Cell Activation and Clonal Selection
643
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
643
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


